Metformin (MFN), a first‐tier hypoglycemic drug for type 2 diabetes (T2D) treatment, can prevent and postpone DN occurrence and progression via several mechanisms, including elevated insulin resistance and glucolipid metabolism, restoration of renal tissue podocalyxin, and several other non‐hypoglycemic mechanisms.7, 8. Here, PODXL is linked to type 2 diabetes mellitus.